88 related articles for article (PubMed ID: 12877587)
1. Development of a water-soluble matrix metalloproteinase inhibitor as an intra-arterial infusion drug for prevention of restenosis after angioplasty.
Masuda T; Nakayama Y
J Med Chem; 2003 Jul; 46(16):3497-501. PubMed ID: 12877587
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of an orally active matrix metalloproteinase inhibitor.
Yamamoto S; Nakatani S; Ikura M; Sugiura T; Nishita Y; Itadani S; Ogawa K; Ohno H; Takahashi K; Nakai H; Toda M
Bioorg Med Chem; 2006 Sep; 14(18):6383-403. PubMed ID: 16765051
[TBL] [Abstract][Full Text] [Related]
3. Development of a polymeric matrix metalloproteinase inhibitor as a bioactive stent coating material for prevention of restenosis.
Nakayama Y; Masuda T
J Biomed Mater Res B Appl Biomater; 2007 Jan; 80(1):260-7. PubMed ID: 16767737
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, radiosynthesis, in vitro and preliminary in vivo evaluation of biphenyl carboxylic and hydroxamic matrix metalloproteinase (MMP) inhibitors as potential tumor imaging agents.
Oltenfreiter R; Staelens L; Hillaert U; Heremans A; Noël A; Frankenne F; Slegers G
Appl Radiat Isot; 2005 Jun; 62(6):903-13. PubMed ID: 15799868
[TBL] [Abstract][Full Text] [Related]
5. A new development of matrix metalloproteinase inhibitors: twin hydroxamic acids as potent inhibitors of MMPs.
Rossello A; Nuti E; Catalani MP; Carelli P; Orlandini E; Rapposelli S; Tuccinardi T; Atkinson SJ; Murphy G; Balsamo A
Bioorg Med Chem Lett; 2005 May; 15(9):2311-4. PubMed ID: 15837315
[TBL] [Abstract][Full Text] [Related]
6. Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET.
Wagner S; Breyholz HJ; Law MP; Faust A; Höltke C; Schröer S; Haufe G; Levkau B; Schober O; Schäfers M; Kopka K
J Med Chem; 2007 Nov; 50(23):5752-64. PubMed ID: 17956082
[TBL] [Abstract][Full Text] [Related]
7. Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides.
Tuccinardi T; Martinelli A; Nuti E; Carelli P; Balzano F; Uccello-Barretta G; Murphy G; Rossello A
Bioorg Med Chem; 2006 Jun; 14(12):4260-76. PubMed ID: 16483784
[TBL] [Abstract][Full Text] [Related]
8. 3-Hydroxy-4-arylsulfonyltetrahydropyranyl-3-hydroxamic acids are novel inhibitors of MMP-13 and aggrecanase.
Noe MC; Snow SL; Wolf-Gouveia LA; Mitchell PG; Lopresti-Morrow L; Reeves LM; Yocum SA; Liras JL; Vaughn M
Bioorg Med Chem Lett; 2004 Sep; 14(18):4727-30. PubMed ID: 15324896
[TBL] [Abstract][Full Text] [Related]
9. Novel matrix metalloproteinase inhibitors: generation of lead compounds by the in silico fragment-based approach.
Takahashi K; Ikura M; Habashita H; Nishizaki M; Sugiura T; Yamamoto S; Nakatani S; Ogawa K; Ohno H; Nakai H; Toda M
Bioorg Med Chem; 2005 Jul; 13(14):4527-43. PubMed ID: 15908222
[TBL] [Abstract][Full Text] [Related]
10. A novel series of highly selective inhibitors of MMP-3.
Whitlock GA; Dack KN; Dickinson RP; Lewis ML
Bioorg Med Chem Lett; 2007 Dec; 17(24):6750-3. PubMed ID: 18029177
[TBL] [Abstract][Full Text] [Related]
11. Galloyl cyclic-imide derivative CH1104I inhibits tumor invasion through suppressing matrix metalloproteinase activity.
Chen MH; Cui SX; Cheng YN; Sun LR; Li QB; Xu WF; Ward SG; Tang W; Qu XJ
Anticancer Drugs; 2008 Nov; 19(10):957-65. PubMed ID: 18827560
[TBL] [Abstract][Full Text] [Related]
12. Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1.
Reiter LA; Robinson RP; McClure KF; Jones CS; Reese MR; Mitchell PG; Otterness IG; Bliven ML; Liras J; Cortina SR; Donahue KM; Eskra JD; Griffiths RJ; Lame ME; Lopez-Anaya A; Martinelli GJ; McGahee SM; Yocum SA; Lopresti-Morrow LL; Tobiassen LM; Vaughn-Bowser ML
Bioorg Med Chem Lett; 2004 Jul; 14(13):3389-95. PubMed ID: 15177439
[TBL] [Abstract][Full Text] [Related]
13. A new 18F-labelled derivative of the MMP inhibitor CGS 27023A for PET: radiosynthesis and initial small-animal PET studies.
Wagner S; Breyholz HJ; Höltke C; Faust A; Schober O; Schäfers M; Kopka K
Appl Radiat Isot; 2009 Apr; 67(4):606-10. PubMed ID: 19167232
[TBL] [Abstract][Full Text] [Related]
14. New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2).
Rossello A; Nuti E; Orlandini E; Carelli P; Rapposelli S; Macchia M; Minutolo F; Carbonaro L; Albini A; Benelli R; Cercignani G; Murphy G; Balsamo A
Bioorg Med Chem; 2004 May; 12(9):2441-50. PubMed ID: 15080939
[TBL] [Abstract][Full Text] [Related]
15. Sultam hydroxamates as novel matrix metalloproteinase inhibitors.
Cherney RJ; Mo R; Meyer DT; Hardman KD; Liu RQ; Covington MB; Qian M; Wasserman ZR; Christ DD; Trzaskos JM; Newton RC; Decicco CP
J Med Chem; 2004 Jun; 47(12):2981-3. PubMed ID: 15163180
[TBL] [Abstract][Full Text] [Related]
16. New beginnings for matrix metalloproteinase inhibitors: identification of high-affinity zinc-binding groups.
Puerta DT; Lewis JA; Cohen SM
J Am Chem Soc; 2004 Jul; 126(27):8388-9. PubMed ID: 15237990
[TBL] [Abstract][Full Text] [Related]
17. Structure-based approach to nanomolar, water soluble matrix metalloproteinases inhibitors (MMPIs).
Attolino E; Calderone V; Dragoni E; Fragai M; Richichi B; Luchinat C; Nativi C
Eur J Med Chem; 2010 Dec; 45(12):5919-25. PubMed ID: 20965620
[TBL] [Abstract][Full Text] [Related]
18. The effect of cyclodextrins on the aqueous solubility of a new MMP inhibitor: phase solubility, 1 H-NMR spectroscopy and molecular modeling studies, preparation and stability study of nebulizable solutions.
Bertholet P; Gueders M; Dive G; Albert A; Barillaro V; Perly B; Cataldo D; Piel G; Delattre L; Evrard B
J Pharm Pharm Sci; 2005 Jul; 8(2):163-74. PubMed ID: 16124927
[TBL] [Abstract][Full Text] [Related]
19. Protective effect of matrix metalloproteinase inhibitors against epidermal basement membrane damage: skin equivalents partially mimic photoageing process.
Amano S; Ogura Y; Akutsu N; Matsunaga Y; Kadoya K; Adachi E; Nishiyama T
Br J Dermatol; 2005 Dec; 153 Suppl 2():37-46. PubMed ID: 16280020
[TBL] [Abstract][Full Text] [Related]
20. Local drug delivery in restenosis injury: thermoresponsive co-polymers as potential drug delivery systems.
Kavanagh CA; Rochev YA; Gallagher WM; Dawson KA; Keenan AK
Pharmacol Ther; 2004 Apr; 102(1):1-15. PubMed ID: 15056495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
